Equities analysts predict that Nabriva Therapeutics plc – (NASDAQ:NBRV) will report sales of $1.32 million for the current quarter, according to Zacks. Four analysts have provided estimates for Nabriva Therapeutics plc -‘s earnings. The highest sales estimate is $1.70 million and the lowest is $1.00 million. The firm is scheduled to issue its next earnings results on Wednesday, November 15th.
According to Zacks, analysts expect that Nabriva Therapeutics plc – will report full year sales of $1.32 million for the current year, with estimates ranging from $4.73 million to $6.20 million. For the next financial year, analysts expect that the business will report sales of $6.79 million per share, with estimates ranging from $2.90 million to $10.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Nabriva Therapeutics plc -.
Nabriva Therapeutics plc – (NASDAQ:NBRV) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million.
Several research firms have recently weighed in on NBRV. Zacks Investment Research upgraded Nabriva Therapeutics plc – from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Thursday, August 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Nabriva Therapeutics plc – in a research note on Friday, June 23rd. Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Nabriva Therapeutics plc – in a research note on Monday, May 15th. ValuEngine lowered Nabriva Therapeutics plc – from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics plc – in a research note on Friday, June 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Nabriva Therapeutics plc – has a consensus rating of “Buy” and a consensus price target of $16.25.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $10.94, for a total transaction of $143,609.38. Following the sale, the insider now directly owns 2,583,229 shares in the company, valued at approximately $28,260,525.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 242,562 shares of company stock worth $2,573,345. 2.75% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nationwide Fund Advisors boosted its position in Nabriva Therapeutics plc – by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares during the last quarter. Royal Bank of Canada boosted its position in Nabriva Therapeutics plc – by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 8,650 shares during the last quarter. Almanack Investment Partners LLC. bought a new position in Nabriva Therapeutics plc – in the 1st quarter valued at $1,870,000. Finally, Wellington Management Group LLP boosted its position in Nabriva Therapeutics plc – by 9.9% in the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the last quarter. Hedge funds and other institutional investors own 68.56% of the company’s stock.
Nabriva Therapeutics plc – (NASDAQ NBRV) traded down 2.38% on Tuesday, reaching $8.60. The company had a trading volume of 26,816 shares. The stock’s market cap is $230.81 million. The company has a 50-day moving average of $9.42 and a 200 day moving average of $10.34. Nabriva Therapeutics plc – has a one year low of $3.52 and a one year high of $12.75.
Nabriva Therapeutics plc – Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics plc - and related companies with MarketBeat.com's FREE daily email newsletter.